Granted Patent B2

US 12,571,803 · App. 17/674,968 · Granted Mar 10, 2026

Inventors: David Wilson (Boxborough, MA); John Henrik Zetterberg (Molnlycke, SE); Kaj Blennow (Kungsbacka, SE); Jeffrey D. Randall (Canton, MA)

Assignee: Quanterix Corporation

G01N33/6896G01N33/54306G01N2333/47G01N2333/4709G01N2800/28G01N2800/52

Abstract

Claims (34)

1 . A method of producing a bodily fluid sample of a patient suspected of having a neurological condition containing an analytically quantified amount of an endogenous phosphorylated tau protein, said method comprising:

(A) obtaining a volume of bodily fluid comprising blood, or a blood component selected from plasma and serum,

(B) diluting the volume of bodily fluid, and

(C) quantifying through the use of an analytical protein concentration measurement assay a concentration of the phosphorylated tau protein in the volume of bodily fluid to produce the bodily fluid sample containing the analytically quantified amount of the endogenous phosphorylated tau protein;

wherein the analytically quantified concentration of the endogenous phosphorylated tau protein contained in the bodily fluid sample is less than about 5 pg/mL, and a limit of quantification of the analytical protein concentration measurement assay used in step (C) for quantifying the concentration of the phosphorylated tau protein is less than about 0.2 pg/mL.

2 . The method of claim 1 , wherein the analytical protein concentration measurement assay used in step (C) comprises:

i. exposing a plurality of capture objects that each include a binding surface having affinity for the phosphorylated tau protein to the volume of bodily fluid;

ii. immobilizing at least some molecules of the phosphorylated tau protein with respect to the plurality of capture objects such that at least some of the capture objects associate with at least one molecule of the phosphorylated tau protein and a statistically significant fraction of the capture objects do not associate with any molecules of the phosphorylated tau protein;

iii. determining a proportion of the plurality of capture objects that associated with a molecule of the phosphorylated tau protein in step ii; and

iv. determining a measure of the concentration of the phosphorylated tau protein in the volume of bodily fluid based at least in part on the proportion determined in step iii.

3 . The method of claim 2 , wherein the plurality of capture objects comprises a plurality of beads.

4 . The method of claim 1 , wherein the analytical protein concentration measurement assay used in step (C) comprises spatially segregating molecules of the phosphorylated tau protein into a plurality of locations, wherein a statistically significant fraction of the locations contain a single molecule of the phosphorylated tau protein and a statistically significant fraction of the locations do not contain any molecules of the phosphorylated tau protein.

5 . The method of claim 4 , wherein the plurality of locations comprises a plurality of reaction vessels.

6 . The method of claim 1 , wherein the phosphorylated tau protein is p-tau-231.

7 . The method of claim 1 , wherein the phosphorylated tau protein is p-tau-181.

8 . The method of claim 1 , wherein the volume of bodily fluid comprises blood.

9 . The method of claim 1 , wherein the volume of bodily fluid comprises plasma.

10 . The method of claim 1 , wherein the volume of bodily fluid comprises serum.

11 . The method of claim 1 , wherein the volume of bodily fluid does not comprise cerebrospinal fluid (CSF).

12 . The method of claim 1 , wherein the patient suspected of having a neurological condition is recovering from a brain injury.

13 . The method of claim 12 , wherein the volume of bodily fluid has been collected from the patient within 12 hours of the brain injury.

14 . The method of claim 12 , wherein the brain injury results from a hypoxic event.

15 . The method of claim 12 , wherein the brain injury comprises a hypoxic event caused by cardiac arrest.

16 . The method of claim 12 , wherein the brain injury comprises a hypoxic event caused by stroke.

17 . The method of claim 12 , wherein the brain injury comprises a hypoxic event caused by an ischemic event.

18 . The method of claim 12 , wherein the brain injury comprises a hypoxic event caused by a thrombosis.

19 . The method of claim 1 , wherein the limit of detection for the analytical protein concentration measurement assay is less than about 0.02 pg/mL.

20 . The method of claim 1 , wherein the analytical protein concentration measurement assay used in step (C) comprises:

i. suspending a plurality of capture objects that each include a binding surface having affinity for the phosphorylated tau protein in the diluted volume of bodily fluid,

ii. immobilizing at least some molecules of the phosphorylated tau protein with respect to at least some of the plurality of capture objects suspended in the diluted volume of bodily fluid such that at least some of the capture objects associate with at least one molecule of the phosphorylated tau protein from the volume of bodily fluid,

iii. interrogating at least some of the capture objects associated with at least one molecule of the phosphorylated tau protein from the volume of bodily fluid; and

iv. determining a measure of the concentration of the phosphorylated tau protein in the volume of bodily fluid based at least in part on the interrogating step performed in step iii.

21 . The method of claim 20 , wherein the plurality of capture objects comprises a plurality of beads.

22 . The method of claim 1 , wherein the limit of quantification for the analytical protein concentration measurement assay is greater than or equal to about 0.01 pg/mL and less than or equal to about 0.2 pg/mL.

Assignments (1)

Continuity (6)

References Cited (400)